CELU240719P5000
- 1.90
- 0.000.00%
Celularity Newsroom
Express News | Celularity Presents Data On T-Cell Therapy Platform At ASCO Annual Meeting; PT-CD16VS Shows Potent Activity And Potential For Combination With Monoclonal Antibodies To Target Multiple Cancers
Express News | Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Express News | Celularity Granted European Patent EP3957315 For Treatment Of Diabetic Peripheral Neuropathy Using Placental Cells
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
Celularity Inc. to Host Investor and Analyst Research & Development Day
FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
Express News | Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
Celularity Inc. (Nasdaq: CELU) today announced that its abstract entitled "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN.
Express News | Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&a Reductions and Manufacturing Ramp for Advanced Biomaterial Products
Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that the U.S. Ce
Express News | Celularity Submits Request To US FDA For Orphan Drug Designation For PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersNuCana (NASDAQ:NCNA) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. The market value of their outstanding shares is at $42.7 million. Kintara Therapeutics (NASDA
Stock Market Resilience: Celularity Inc's (CELU) Remarkable Turnaround
During Tuesday's extended trading session, Celularity Inc. (NASDAQ: CELU) saw a notable uptick in its stock price, gaining 23.57 percent to $7.23 per share. In contrast to CELU's performance during the regular session, which saw a 15.30% loss and close at $5.89, the stock saw a rise in value as traders anticipated a noteworthy development. ...
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived From Human Placental Cells
FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
There's No Escaping Celularity Inc.'s (NASDAQ:CELU) Muted Revenues Despite A 29% Share Price Rise
Celularity Inc. (NASDAQ:CELU) shares have continued their recent momentum with a 29% gain in the last month alone. Unfortunately, the gains of the last month did little to right the losses of the l
Celularity To Carry Out 1-for-10 Reverse Stock Split On February 29th, 2024
February 28th - $Celularity(CELU.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from February 29th, 2024.$Celularity(CELU.
Workday, Domino's And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Domino's Pizza, Inc. (NYSE:DPZ) to report quart